For many women, the thought of a Pap smear is uncomfortable, often ranking alongside dental visits as something to avoid. Dr. Lily Wong, a family doctor at The London Medical Clinic in Hong Kong, acknowledges that discomfort is a major barrier to routine cervical cancer screening. Despite this, the Pap smear, developed in 1928 by Dr. Georgios Papanicolaou, has played a crucial role in detecting early signs of cervical cancer, significantly reducing its incidence worldwide.
Cervical cancer, primarily caused by high-risk strains of the human papillomavirus (HPV), has become more preventable with the introduction of the HPV vaccine. Studies show that girls vaccinated before the age of 17 have an 88% lower risk of developing the disease. The vaccine is most effective when administered before the onset of sexual activity, making it recommended for both boys and girls as young as nine. HPV is also linked to other cancers, including those of the throat, tonsils, anus, and penis, further reinforcing the vaccine’s importance.
Despite awareness campaigns, many women still skip Pap smears. The World Health Organization identifies cervical cancer as the fourth most common cancer among women, with over 660,000 new cases reported in 2022. A woman dies from it every two minutes. In Hong Kong, 596 new cases were recorded in 2021, with nearly three-quarters occurring in women aged 25 to 64. Almost half were diagnosed at an advanced stage, highlighting the need for regular screenings.
Cultural and societal factors also contribute to low screening rates. Stigma surrounding reproductive health, concerns about modesty, and fear of discomfort often deter women from seeking regular tests. However, the development of non-invasive alternatives may encourage more participation.
The La Rosee PadX sanitary pad offers a discreet at-home screening option. Developed by femtech start-up WomenX Biotech, the pad detects 24 HPV variants through menstrual blood. Women wear it during their period, seal it in a special bag, and send it to a designated medical lab. In clinical trials, the PadX showed a 99.2% accuracy rate, making it a promising alternative for those hesitant about traditional Pap smears.
Other self-administered tests, such as the Papcup from Imperial College London and the Teal Health Cervical Cancer Screening device undergoing FDA review, further demonstrate the global push toward more accessible cervical cancer screening. A newly developed urine test available in Hong Kong can detect 14 high-risk HPV types in both men and women.
As medical advancements continue, these innovations could redefine cervical cancer prevention, making routine screening more comfortable and widely adopted.
READ MORE: